Cost-effectiveness analysis of efavirenz versus ainuovirine in people living with HIV initiating first-line combination antiretroviral therapy.

Yang C, Mi Y, Zeng Y, Cheng F, Zeng H, Zhou M

Open source

DOI
10.1136/bmjopen-2026-120914
Published
2026 Sep 18
Container
BMJ open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2026-120914,
  title = {Cost-effectiveness analysis of efavirenz versus ainuovirine in people living with HIV initiating first-line combination antiretroviral therapy.},
  author = {Yang C and Mi Y and Zeng Y and Cheng F and Zeng H and Zhou M},
  year = {2026},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2026-120914},
  url = {https://doi.org/10.1136/bmjopen-2026-120914}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness analysis of efavirenz versus ainuovirine in people living with HIV initiating first-line combination antiretroviral therapy.
AU  - Yang C
AU  - Mi Y
AU  - Zeng Y
AU  - Cheng F
AU  - Zeng H
AU  - Zhou M
PY  - 2026
JO  - BMJ open
DO  - 10.1136/bmjopen-2026-120914
UR  - https://doi.org/10.1136/bmjopen-2026-120914
ER  - 

APA

C, Y., Y, M., Y, Z., F, C., H, Z., & M, Z. (2026). Cost-effectiveness analysis of efavirenz versus ainuovirine in people living with HIV initiating first-line combination antiretroviral therapy.. BMJ open. https://doi.org/10.1136/bmjopen-2026-120914

Source records